FLOW CYTOMETRY, CD 138

The Flow Cytometry CD138 Test is an advanced immunophenotyping assay used to detect and quantify CD138 (Syndecan-1) expression on plasma cells. CD138 is one of the most important markers used in flow cytometry for identifying plasma cells and evaluating plasma cell disorders, including Multiple Myeloma, Plasma Cell Leukemia, and other monoclonal plasma cell proliferative conditions.

Plasma cells are specialized immune cells derived from B lymphocytes and are responsible for producing antibodies that help protect the body against infections. Under normal circumstances, plasma cells are present in small numbers within the bone marrow. However, abnormal proliferation of plasma cells can lead to plasma cell neoplasms and hematological malignancies.

Flow cytometry allows rapid analysis of thousands of cells simultaneously, helping identify abnormal plasma cell populations based on their immunophenotypic characteristics. CD138 is typically assessed alongside other markers such as CD38, CD19, CD45, CD56, CD117, and Kappa/Lambda light chains to accurately classify plasma cell disorders.

The test is commonly performed on bone marrow aspirates and plays a vital role in diagnosis, disease monitoring, treatment response assessment, and minimal residual disease evaluation.

Benefits of the Test

• Identifies plasma cell populations accurately
• Supports diagnosis of Multiple Myeloma
• Helps classify plasma cell neoplasms
• Assists in treatment monitoring
• Detects abnormal plasma cell immunophenotypes
• Supports minimal residual disease assessment in selected cases

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD138 testing for:

• Suspected Multiple Myeloma
• Plasma cell dyscrasia evaluation
• Monoclonal gammopathy assessment
• Abnormal serum protein electrophoresis findings
• Bone marrow disorder investigation
• Monitoring treatment response
• Follow-up of plasma cell malignancies
• Evaluation of unexplained bone marrow abnormalities

The test provides detailed information about plasma cell populations and helps clinicians determine disease burden and progression.

Preparation Before Test

The test may require:

• Bone marrow aspirate (most commonly)
• Peripheral blood sample (selected cases)
• Other clinically relevant specimens

Preparation generally includes:

• No fasting is required
• Follow physician instructions regarding specimen collection
• Inform your healthcare provider about current medications and treatments

The sample is processed using specialized flow cytometry equipment and analyzed by hematopathology experts.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on laboratory workflow and panel complexity.

Who Should Take This Test?

• Patients with suspected Multiple Myeloma
• Individuals with monoclonal gammopathy
• Patients with plasma cell neoplasms
• Individuals undergoing bone marrow evaluation
• Patients with abnormal immunoglobulin levels
• Individuals referred by hematologists or oncologists

Clinical Significance

CD138-positive plasma cells may be identified in:

• Multiple Myeloma
• Plasma Cell Leukemia
• Monoclonal Gammopathy of Undetermined Significance (MGUS)
• Smoldering Multiple Myeloma
• Solitary Plasmacytoma
• Other Plasma Cell Dyscrasias

Abnormal plasma cell immunophenotypes, especially when associated with monoclonal light chain restriction, may indicate a plasma cell malignancy and require further clinical correlation.

Important Note

CD138 is highly valuable for plasma cell identification but must always be interpreted with additional flow cytometry markers, bone marrow morphology, serum protein studies, immunofixation, and clinical findings for accurate diagnosis and disease classification.